Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1958 1
1963 2
1964 2
1966 1
1970 1
1972 1
1973 2
1975 1
1976 3
1977 1
1978 3
1979 6
1980 8
1981 10
1982 18
1983 22
1984 22
1985 30
1986 34
1987 68
1988 63
1989 69
1990 77
1991 82
1992 111
1993 79
1994 89
1995 90
1996 76
1997 93
1998 108
1999 139
2000 131
2001 119
2002 105
2003 123
2004 131
2005 135
2006 152
2007 163
2008 178
2009 188
2010 210
2011 216
2012 214
2013 233
2014 206
2015 226
2016 233
2017 201
2018 206
2019 218
2020 226
2021 255
2022 232
2023 202
2024 81

Text availability

Article attribute

Article type

Publication date

Search Results

5,394 results

Results by year

Filters applied: . Clear all
Page 1
Ulcerative colitis.
Le Berre C, Honap S, Peyrin-Biroulet L. Le Berre C, et al. Lancet. 2023 Aug 12;402(10401):571-584. doi: 10.1016/S0140-6736(23)00966-2. Lancet. 2023. PMID: 37573077 Review.
The aim of medical management is, first, to induce a rapid clinical response and normalise biomarkers and, second, to maintain clinical remission and reach endoscopic normalisation to prevent long-term disability. Treatments for inducing remission include 5-aminosalicyl …
The aim of medical management is, first, to induce a rapid clinical response and normalise biomarkers and, second, to maintain clinical remi …
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Le Berre C, et al. Expert Opin Biol Ther. 2020 Apr;20(4):363-378. doi: 10.1080/14712598.2019.1666101. Epub 2019 Sep 18. Expert Opin Biol Ther. 2020. PMID: 31498003 Review.
Introduction: For 30 years, 5-aminosalicylic acid (5-ASA) has been the backbone of therapeutic management in patients with ulcerative colitis (UC). ...
Introduction: For 30 years, 5-aminosalicylic acid (5-ASA) has been the backbone of therapeutic management in patients w …
5-Aminosalicylic acid.
Iida T, Onodera K, Nakase H. Iida T, et al. Nihon Rinsho. 2017 Mar;75(3):392-397. Nihon Rinsho. 2017. PMID: 30566780 English, Japanese.
5-aminosalicylic acid suppresses osteoarthritis through the OSCAR-PPARgamma axis.
Kim J, Ryu G, Seo J, Go M, Kim G, Yi S, Kim S, Lee H, Lee JY, Kim HS, Park MC, Shin DH, Shim H, Kim W, Lee SY. Kim J, et al. Nat Commun. 2024 Feb 3;15(1):1024. doi: 10.1038/s41467-024-45174-6. Nat Commun. 2024. PMID: 38310093 Free PMC article.
Despite affecting millions of patients, effective and safe disease-modifying osteoarthritis drugs are lacking. Here we reveal an unexpected role for the small molecule 5-aminosalicylic acid (5-ASA), which is used as an anti-inflammatory drug in ulcerative col …
Despite affecting millions of patients, effective and safe disease-modifying osteoarthritis drugs are lacking. Here we reveal an unexpected …
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Baumgart DC, Sandborn WJ. Baumgart DC, et al. Lancet. 2007 May 12;369(9573):1641-57. doi: 10.1016/S0140-6736(07)60751-X. Lancet. 2007. PMID: 17499606 Review.
In this paper we discuss the current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management, and provide diagnostic and therapeutic algorithms. We crit …
In this paper we discuss the current diagnostic approach, their pathology, natural course, and common complications, the assessment of disea …
5-Aminosalicylic acid and chemoprevention: does it work?
Lopez A, Peyrin-Biroulet L. Lopez A, et al. Dig Dis. 2013;31(2):248-53. doi: 10.1159/000353806. Epub 2013 Sep 6. Dig Dis. 2013. PMID: 24030235 Review.
5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD). ...
5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD). ...
5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Hauso Ø, Martinsen TC, Waldum H. Hauso Ø, et al. Scand J Gastroenterol. 2015 Aug;50(8):933-41. doi: 10.3109/00365521.2015.1018937. Epub 2015 Mar 2. Scand J Gastroenterol. 2015. PMID: 25733192 Review.
The active part of salazopyrin, the oldest drug in use in the treatment of ulcerative colitis, is 5-aminosalicylic acid (5-ASA). In the present paper, we wanted to discuss the etiology and pathogenesis of ulcerative colitis in relation to the beneficial effec …
The active part of salazopyrin, the oldest drug in use in the treatment of ulcerative colitis, is 5-aminosalicylic acid …
A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems.
Shahdadi Sardo H, Saremnejad F, Bagheri S, Akhgari A, Afrasiabi Garekani H, Sadeghi F. Shahdadi Sardo H, et al. Int J Pharm. 2019 Mar 10;558:367-379. doi: 10.1016/j.ijpharm.2019.01.022. Epub 2019 Jan 18. Int J Pharm. 2019. PMID: 30664993 Review.
Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as rapid onset of action and reduction of the dosage of the drug as well as minimization of harmful side effects. 5-aminosalicylic …
Site-specific colon drug delivery is a practical approach for the treatment of local diseases of the colon with several advantages such as r …
5,394 results